As for the limitations of the current study, although the EGFR downstream effector RAS is a major proto-oncogene for human cancer, the RAS mutation is not very prevalent in patients with liver cancers, with 7% of patients having KRAS mutations and 4% of patients having HRAS mutations [20]. The gene discussed is EGFR; the disease is liver cancer.